Published in
Elsevier, The Lancet Oncology, 12(22), p. 1705-1720, 2021
DOI: 10.1016/s1470-2045(21)00535-0
Links
Tools
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Journal article published in 2021 by
Francesca Gay,
Pellegrino Musto,
Delia Rota-Scalabrini,
Luca Bertamini 
,
Angelo Belotti,
Monica Galli,
Massimo Offidani,
Elena Zamagni ,
Antonio Ledda,
Mariella Grasso,
Stelvio Ballanti,
Antonio Spadano,
Michele Cea,
Francesca Patriarca,
Mattia D'Agostino
and other authors.
,
Angelo Belotti,
Monica Galli,
Massimo Offidani,
Elena Zamagni ,
Antonio Ledda,
Mariella Grasso,
Stelvio Ballanti,
Antonio Spadano,
Michele Cea,
Francesca Patriarca,
Mattia D'Agostino
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 